Clinical Trials
45 trialsNCT04010357 2026-05-12
Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC
Case Comprehensive Cancer Center
Phase 2 Completed
NCT07487129 2026-03-23
Clinical and P
Beni-Suef University
Phase 4 Completed
NCT03643510 2026-03-16
Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT04391595 2026-03-06
LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients
St. Joseph's Hospital and Medical Center, Phoenix
Phase EARLY_PHASE1 Completed
NCT05999968 2026-03-05
Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment
Eli Lilly and Company
Phase 1 Completed
NCT04238819 2026-03-02
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Eli Lilly and Company
Phase 1/2 Completed
NCT04481113 2026-01-29
Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer
OHSU Knight Cancer Institute
Phase 1 Completed
NCT04603183 2025-12-12
ABIGAIL
MedSIR
Phase 2 Completed
NCT03280563 2025-11-10
MORPHEUS HR+BC
Hoffmann-La Roche
Phase 1/2 Completed
NCT04049227 2025-10-20
Abemaciclib and Letrozole in Treating Patients With Endometrial Cancer
Northwestern University
Phase EARLY_PHASE1 Completed
NCT04627064 2025-07-25
ABEMA Alone or in COMBO With MK-6482
Dana-Farber Cancer Institute
Phase 1 Completed
NCT04352777 2025-07-20
Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer
Duke University
Phase 2 Completed
NCT03099174 2025-06-24
This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer
Boehringer Ingelheim
Phase 1 Completed
NCT04552769 2025-06-05
Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
Stanford University
Phase 2 Completed
NCT05759949 2025-05-16
First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors
Relay Therapeutics, Inc.
Phase 1 Completed
NCT03732703 2025-02-14
MyDRUG
Multiple Myeloma Research Consortium
Phase 1/2 Completed
NCT04432454 2025-02-13
ELAINEII
Sermonix Pharmaceuticals Inc.
Phase 2 Completed
NCT02675231 2024-11-26
monarcHER
Eli Lilly and Company
Phase 2 Completed
NCT02791334 2024-09-27
PACT
Eli Lilly and Company
Phase 1 Completed
NCT01394016 2024-09-19
A Phase 1 Study of LY2835219 In Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT04408924 2024-06-25
CYCLONE 1
Eli Lilly and Company
Phase 2 Completed
NCT03703466 2024-04-02
A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast Cancer
Eli Lilly and Company
Phase 2 Completed
NCT03339843 2024-03-15
MiMe-A
Jules Bordet Institute
Phase 2 Completed
NCT04707196 2023-11-24
A Study of Abemaciclib in Indian Women With Advanced Breast Cancer
Eli Lilly and Company
Phase 4 Completed
NCT02644460 2023-10-26
AflacST1501
Emory University
Phase 1 Completed
NCT01739309 2023-09-21
Study of LY2835219 for Mantle Cell Lymphoma
Eli Lilly and Company
Phase 2 Completed
NCT03356223 2023-02-23
ABORL
Centre Leon Berard
Phase 2 Completed
NCT04514159 2023-02-01
A Study of ZN-c5 and Abemaciclib in Participants With Breast Cancer
Zeno Alpha Inc.
Phase 1 Completed
NCT02857270 2022-11-22
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
Eli Lilly and Company
Phase 1 Completed
NCT02688088 2022-10-18
A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body
Eli Lilly and Company
Phase 1 Completed
NCT01655225 2022-04-08
A Study of LY3023414 in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT03292250 2022-03-29
Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]
Seoul National University Hospital
Phase 2 Completed
NCT04071262 2021-09-21
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Therapies in Japanese Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT02450539 2021-08-13
A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer
Eli Lilly and Company
Phase 2 Completed
NCT02308020 2020-12-19
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain
Eli Lilly and Company
Phase 2 Completed
NCT02919696 2020-09-25
A Study of Abemaciclib (LY2835219) in Native Chinese Participants With Advanced and/or Metastatic Cancers
Eli Lilly and Company
Phase 1 Completed
NCT02079636 2020-09-11
A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)
Eli Lilly and Company
Phase 1 Completed
NCT02014129 2020-08-24
A Study of LY2835219 in Japanese Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT02411591 2020-07-09
A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC)
Eli Lilly and Company
Phase 1 Completed
NCT02441946 2020-06-17
neoMONARCH
Eli Lilly and Company
Phase 2 Completed
NCT02102490 2020-01-21
MONARCH 1
Eli Lilly and Company
Phase 2 Completed
NCT02981342 2019-11-20
A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma
Eli Lilly and Company
Phase 2 Completed
NCT02745769 2019-03-05
A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents
Eli Lilly and Company
Phase 1 Completed
NCT02117648 2019-01-07
A Study of LY2835219 in Participants With Cancer
Eli Lilly and Company
Phase 1 Completed
NCT02831530 2018-03-29
ABC-POP
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Completed